Aptinyx, which is developing novel small molecule therapeutics for neurological disorders, raised $102 million by offering 6.4 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 5.3 million shares. Existing investors intended to buy up to $30 million on the IPO, representing 29% of the deal.
Aptinyx plans to list on the Nasdaq under the symbol APTX. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
